Menu

Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Biomarkers for breast DCIS progression

Centre for Cancer Prevention

Project Investigator:  Professor Jack Cuzick

Overview

The appropriate management of DCIS (ductal carcinoma in situ) is one of the biggest challenges in breast cancer management today.

We are undertaking biomarker studies in the UK/ANZ 2x2 trial of tamoxifen and radiotherapy in 1,701 women with locally excised DCIS.  Biomarker work is well underway looking at IHC markers (ER, PgR, HER2, Ki67 and others) and expression profiles, but no results are available at this time.

Diagnostic blocks from more than 900 women have been collected.

Long term follow up is continuing and the 12.7 year median follow-up was recently presented which showed a continuing benefit for radiotherapy on local recurrence and a benefit of tamoxifen only for new contralateral tumours. No effect on distant recurrence of breast cancer or other deaths have been seen.

A new classification system for DCIS has been derived for the material in this trial.

 

 

 

Return to top